Jubilant Pharmova Limited has announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported a consolidated revenue of ₹82,796 million for the year, reflecting steady growth. Alongside the financial performance, the Board of Directors has recommended a final dividend of 500%, amounting to ₹5 per equity share of ₹1 face value, for the fiscal year ended March 31, 2026.
Financial Performance Overview
For the financial year ended March 31, 2026, Jubilant Pharmova achieved a consolidated revenue from operations of ₹82,796 million, compared to ₹72,345 million in the previous year. The consolidated profit for the period stood at ₹3,975 million. The company’s performance reflects its ongoing operational execution, with the audit report issued by the Statutory Auditors carrying an unmodified opinion.
Dividend Recommendation
The Board of Directors has recommended a final dividend of 500%, which translates to ₹5 per equity share of face value ₹1 each for the financial year ended March 31, 2026. This dividend payment is subject to approval by shareholders at the upcoming Annual General Meeting. The company has fixed Friday, July 24, 2026, as the record date to determine the eligibility of shareholders for the dividend payout.
Key Operational Highlights
The consolidated results highlight the company’s diverse portfolio performance, including Radiopharma and Allergy Immunotherapy segments. The Board meeting held on May 22, 2026, also noted that these financial results were prepared in strict accordance with Indian Accounting Standards (Ind AS). The management continues to focus on business growth, internal efficiencies, and navigating the evolving regulatory landscape, including the implementation of new labor and tax frameworks.
Source: BSE
